Factors Associated with Ovarian Hyperstimulation Syndrome (OHSS) Severity in Women With Polycystic Ovary Syndrome Undergoing IVF/ICSI

Bo Sun1,2,3,4†, Yujia Ma1,2,3,4†, Lu Li1,2,3,4, Linli Hu1,2,3,4, Fang Wang1,2,3,4, Yile Zhang1,2,3,4, Shanjun Dai1,2,3,4 and Yingpu Sun1,2,3,4*

1 Center for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, 2 Henan Key Laboratory of Reproduction and Genetics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, 3 Henan Provincial Obstetrical and Gynecological Diseases (Reproductive Medicine) Clinical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, 4 Henan Engineering Laboratory of Preimplantation Genetic Diagnosis and Screening, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Introduction: Age, polycystic ovary syndrome (PCOS), low body mass index (BMI), high antral follicle count (AFC), increased anti-Muller hormone (AMH) levels, and elevated serum estradiol (E2) concentrations are risk factors for ovarian hyperstimulation syndrome (OHSS). However, data on the relationship between risk factors and OHSS severity in patients with PCOS are rare.

Objective: This retrospective study examined the risk factors for OHSS and their effect on OHSS severity in patients with PCOS undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI).

Method: The records of 2,699 women were reviewed and included in this study. These women were diagnosed with PCOS during their first IVF/ICSI cycle between January 2010 and December 2017. We analyzed the association between each of the interrogated risk factors (including female age, BMI, AFC, basal serum FSH and E2, and the number of oocytes retrieved) and OHSS. The effects of each risk factor on OHSS severity were further explored. Logistic regression was performed as part of the above analysis.

Results: Of the 2,699 women with PCOS who underwent assisted reproductive technology (ART), 75.2% had a normal response to controlled ovarian hyperstimulation (COH), while 24.8% developed OHSS. All OHSS patients were younger and had lower BMIs and basal serum follicle-stimulating hormone (FSH) and E2 levels but higher AFCs than those in the normal group. AFC demonstrated a strong correlation with OHSS, with a cutoff value of 24 in patients with PCOS. BMI and AFC were not different between the mild and moderate OHSS groups. Basal serum E2 showed a strong correlation with OHSS severity, with a cutoff value of 37.94 pg/ml.
INTRODUCTION

Ovarian hyperstimulation syndrome (OHSS) is a complication that occurs frequently during controlled ovarian stimulation (COH) (1, 2). Moderate-to-severe OHSS occurs in 1%–5% of assisted reproductive technology (ART) cycles (3). OHSS is characterized by bilateral cystic enlargement of highly luteinized ovaries. Secondary complications, such as vascular hyperpermeability, which causes mortality in rare cases (4), as well as hemorrhagic ovarian cysts (5), also characterize OHSS. Because symptoms of the mild form of OHSS might go unnoticed, its morbidity is most likely underestimated. Moderate OHSS clinical manifestations include abdominal distention, nausea, and vomiting, as well as poor appetite. A total of 1.9% of patients are hospitalized because of effects that include hepatorenal failure, acute respiratory distress syndrome, hemorrhage from ovarian rupture, and thromboembolism. Severe OHSS cases may even result in death.

Previous studies have shown that polycystic ovary syndrome (PCOS), a history of OHSS, young age, low body mass index (BMI), and a high antral follicle count (AFC) might lead to OHSS. Other risk factors include a history of allergies, high levels of anti-Muller hormone (AMH), high doses of gonadotropins, and high serum E2 levels (>3,500 pg/ml) are particularly associated with an increased risk of OHSS in patients undergoing fertility treatment (3, 17). However, the above indicators do not offer any further refinement or indications of the severity of OHSS. Previous studies have evaluated the risk factors for OHSS in the whole population being treated for infertility, especially non-polycystic ovary syndrome (NPCOS) patients, but the risk factors for OHSS in PCOS patients are still unclear. This retrospective study examines the risk factors for OHSS and their effect on OHSS severity in patients with PCOS undergoing IVF/ICSI treatment, which may help clinicians advance the management of patients with PCOS prevent the occurrence of OHSS.

MATERIALS AND METHODS

Study Design and Patients

A total of 50,518 records of female patients were reviewed in this study. A total of 2,699 women who attended the Center for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University from January 2010 to December 2017 were included (Supplement Figure 1). The participants had undergone the first in vitro fertilization (IVF)/intracytoplasmic sperm injection-embryo transfer (ICSI-ET) cycles using long agonist protocols and were diagnosed with PCOS based on the 2003 Rotterdam criteria. The diagnosis was based on at least two of the following three criteria: 1) Oligo/anovulation; 2) Clinical and/or biochemical signs of hyperandrogenism; or 3) Polycystic ovaries as well as exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing’s syndrome) (18). Hyperandrogenism was determined based on the total serum T level. Polycystic ovaries were defined as ≥12 follicles of 2–9 mm in a single ovary or an ovarian volume of >10 cm3 on ultrasonography. Patients who underwent short ovarian stimulation protocols, and basal serum T level of >0.7 ng/ml and had severe systemic diseases, such as liver, cardiovascular, or kidney diseases, were excluded. Other exclusion factors included benign or malignant gynecological tumors (ovarian tumor, endometrial tumor, and cervical cancer), metabolic disorders, chromosomal abnormalities, endometriosis, and congenital uterine malformations.

Grouping Method

Patients with PCOS were divided into two groups based on the presence of OHSS (normal group vs. OHSS group). And the OHSS group was divided into mild OHSS group and moderate OHSS group according to the following criteria. (since we do not have many severe OHSS patients in our center, we don’t discuss here). The diagnosis of OHSS was based on the 2016 published clinical practice guidelines, which highlight moderate abdominal pain, nausea, and vomiting as OHSS symptoms (17). Mild hyperstimulation was defined as bilateral ovarian enlargement, while moderate hyperstimulation was identified based on documentation of patient discomfort, bloating, ascites or

Conclusions: AFC is a strong marker of OHSS, and basal serum E2 is the best predictor of OHSS severity in women with PCOS undergoing IVF treatment.

Keywords: polycystic ovarian syndrome, ovarian hyperstimulation syndrome, body mass index, antral follicle count, estradiol
Ovarian Stimulation Protocols

All the included patients used long-acting protocol and they were given a starting dose of 87.5–225 IU human recombinant follicle stimulating hormone (rFSH). Ovulation was induced using gonadotropin (Gn), and the dose was adjusted in a timely manner depending on the number, size, and growth of follicles. The clinician determined the increase or decrease based on hormone levels and follicular development. HCG injection depended on the size of one primary follicle (≥20 mm), with the diameter of the other follicle being ≥18 mm or more than 2/3 of the follicles having a follicle diameter ≥14 mm. The patient’s clinical serum E2 levels and follicle condition determined the trigger drug and HCG exposure time. Eggs were retrieved 36–37 h after HCG administration. Conventional IVF or ICSI was performed based on the semen quality and previous fertilization history. In summary, all patients were treated with a gonadotropin releasing hormone (GnRH) agonist protocol to achieve a receptive endometrium for the implantation of embryos. Intramuscular injection of progesterone was used for endometrial transformation. Luteal gel was used for luteal support after transplantation. HCG was not used.

Statistical Methods

R version 3.4.4 (14) and SAS 9.4 (SAS Institute, Cary, NC, USA) were used to analyze the data. The numerical data are presented as the mean with standard deviation (SD), while categorical variables are shown as % (n/N). A t test was used for continuous variables, while the chi-square test was used for categorical variables. We performed logistic regression to explore the effects of each risk factor on OHSS and OHSS severity. The curve fit was used to clarify the relationships between OHSS and antral follicular count and basal follicle stimulating hormone (FSH). The results are reported as adjusted odds ratios (aORs) with 95% confidence intervals (CIs). Two-tailed P<0.05 was considered statistically significant.

RESULTS

Baseline Characteristics

Of the 50,518 ART patients who began treatment between 2010 and 2017, 2,699 who had PCOS were included in the present study. There were 2,030 (75.2%) patients who had a normal response to COH, while 669 (24.8%) developed OHSS in response to COH (Table 1). The women in OHSS group were younger (29.12 ± 3.82 VS 28.60 ± 3.59), had a lower BMI (24.08 ± 3.57 VS 23.72 ± 3.54) as well as a lower basal serum FSH (5.94 ± 1.35 VS 5.59 ± 1.34) and E2 (46.92 ± 33.96 VS 43.99 ± 30.55) levels. On the other hand, OHSS patients showed a higher basal serum PRL (17.15 ± 12.50 VS 17.83 ± 11.30) and AFC (21.54 ± 4.34 VS 23.05 ± 2.60). As hypothesized, age, BMI or AFC were significantly different between the two groups (P = 0.0036; P = 0.0393; P < 0.0001), indicating that they might be important predictors of OHSS. And the basal serum FSH levels were significantly higher in OHSS group compared with control group (P < 0.0001). The follow-up results were used to evaluate the differences in risk factors between the two groups.

Table 1 | Baseline characteristics and hormonal profiles according to ovarian hyperstimulation syndrome (OHSS) status in women with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI).

| Variables | Normal | OHSS | P value |
|-----------|--------|------|---------|
| Number of patients | 2030 | 669 |        |
| Age (y) | 29.12 ± 3.82 | 28.69 ± 3.69 | 0.0036 |
| Weight (kg) | 62.80 ± 9.78 | 62.12 ± 9.90 | 0.1307 |
| BMI* | 24.08 ± 3.57 | 23.72 ± 3.54 | 0.0393 |
| Duration of infertility | 4.33 ± 2.22 | 4.23 ± 2.12 | 0.4428 |
| Antral follicular count* | 21.54 ± 4.34 | 23.05 ± 2.60 | <0.0001 |
| FSH (mIU/mL)* | 5.94 ± 1.35 | 5.59 ± 1.34 | <0.0001 |
| E2 (pg/mL)* | 46.92 ± 33.96 | 43.99 ± 30.55 | 0.0338 |
| P4 (ng/mL) | 0.76 ± 0.75 | 0.77 ± 0.78 | 0.7538 |
| PRL (ng/mL)* | 17.15 ± 12.50 | 17.83 ± 11.30 | 0.0011 |
| LH (mIU/mL) | 8.70 ± 5.34 | 9.14 ± 5.56 | 0.0479 |
| T (ng/mL) | 0.37 ± 0.14 | 0.37 ± 0.14 | 0.6662 |
| Type of infertility | | | |
| Secondary infertility | 646 | 210 | 0.8348 |
| Primary infertility | 1384 | 459 | 0.6618 |
| Treatment | | | |
| ICSI | 417 | 106 | 0.0076 |
| IVF | 1613 | 563 | 0.1615 |
| Proposal type | | | |
| Follicular phase long-acting protocol* | 969 | 462 | 0.0001 |
| Long-acting protocol* | 1061 | 37 | 0.0094 |

Data are mean ± standard deviation or N (% of response group). FSH, follicle-stimulating hormone; E2, estradiol; P4, progesterone; LH, luteinizing hormone; PRL, pituitary prolactin; T, testosterone; BMI, body mass index.

*They are both long agonist protocols, the difference between them is that the time of ago

A total of 128 (19.5%) of the cycles involved mild OHSS, while 527 (80.5%) involved moderate OHSS. The baseline characteristics of the mild and moderate OHSS patients are listed in Table 2. Briefly, the mild OHSS group was older (29.42 ± 3.53 VS 28.41 ± 3.59, P=0.0027) and had a higher basal serum FSH level (17.15 ± 12.50 VS 17.83 ± 11.30) and AFC (21.54 ± 3.44 VS 23.05 ± 2.60). As hypothesized, age, BMI or AFC were significantly different between the two groups (P = 0.0036; P = 0.0393; P < 0.0001), indicating that they might be important predictors of OHSS. And the basal serum FSH level was higher in moderate OHSS group compared with control group (P < 0.0001). The follow-up results were used to evaluate the differences in risk factors between the two groups.

Table 2 | Baseline characteristics and hormonal profiles according to ovarian hyperstimulation syndrome (OHSS) status in women with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI).

|Variables | Normal | OHSS | P value |
|-----------|--------|------|---------|
| Age (y) | 29.12 ± 3.82 | 28.69 ± 3.69 | 0.0036 |
| Weight (kg) | 62.80 ± 9.78 | 62.12 ± 9.90 | 0.1307 |
| BMI* | 24.08 ± 3.57 | 23.72 ± 3.54 | 0.0393 |
| Duration of infertility | 4.33 ± 2.22 | 4.23 ± 2.12 | 0.4428 |
| Antral follicular count* | 21.54 ± 4.34 | 23.05 ± 2.60 | <0.0001 |
| FSH (mIU/mL)* | 5.94 ± 1.35 | 5.59 ± 1.34 | <0.0001 |
| E2 (pg/mL)* | 46.92 ± 33.96 | 43.99 ± 30.55 | 0.0338 |
| P4 (ng/mL) | 0.76 ± 0.75 | 0.77 ± 0.78 | 0.7538 |
| PRL (ng/mL)* | 17.15 ± 12.50 | 17.83 ± 11.30 | 0.0011 |
| LH (mIU/mL) | 8.70 ± 5.34 | 9.14 ± 5.56 | 0.0479 |
| T (ng/mL) | 0.37 ± 0.14 | 0.37 ± 0.14 | 0.6662 |
| Type of infertility | | | |
| Secondary infertility | 646 | 210 | 0.8348 |
| Primary infertility | 1384 | 459 | 0.6618 |
| Treatment | | | |
| ICSI | 417 | 106 | 0.0076 |
| IVF | 1613 | 563 | 0.1615 |
| Proposal type | | | |
| Follicular phase long-acting protocol* | 969 | 462 | 0.0001 |
| Long-acting protocol* | 1061 | 37 | 0.0094 |

Data are mean ± standard deviation or N (% of response group). FSH, follicle-stimulating hormone; E2, estradiol; P4, progesterone; LH, luteinizing hormone; PRL, pituitary prolactin; T, testosterone; BMI, body mass index.

*They are both long agonist protocols, the difference between them is that the time of agonist-using, the former one is in the follicular phase, while the latter one is in the luteal phase.

P < 0.05.
TABLE 2 | Baseline characteristics and hormonal profiles according to polycystic ovarian hyperstimulation syndrome (OHSS) severity in women with polycystic ovary syndrome (PCOS) undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI).

| Variables                | Mild OHSS     | Moderate OHSS | P value |
|--------------------------|---------------|---------------|---------|
| Number of patients       | 128           | 527           |         |
| Age*                     | 29.42 ± 3.53  | 28.41 ± 3.59  | 0.0027  |
| Weight                   | 61.89 ± 10.17 | 62.05 ± 9.83  | 0.7585  |
| BMI                      | 23.90 ± 3.76  | 23.65 ± 3.46  | 0.6651  |
| Duration of infertility  | 4.54 ± 2.41   | 4.16 ± 2.04   | 0.2414  |
| Antral follicle count     | 22.80 ± 2.84  | 23.13 ± 2.42  | 0.056   |
| Baseline hormone levels  |               |               |         |
| FSH (mIU/ml)*            | 5.89 ± 1.42   | 5.48 ± 1.27   | 0.0026  |
| E2 (pg/ml)*              | 38.05 ± 30.90 | 45.40 ± 29.61 | <0.0001 |
| P4 (ng/ml)               | 0.74 ± 0.73   | 0.77 ± 0.70   | 0.3422  |
| PRL (ng/ml)              | 20.92 ± 29.50 | 19.95 ± 23.97 | 0.8636  |
| LH (mlU/ml)              | 9.26 ± 8.07   | 9.03 ± 6.40   | 0.7007  |
| T*                       | 0.34 ± 0.14   | 0.38 ± 0.14   | 0.01    |
| Type of infertility      |               |               |         |
| Secondary infertility    | 42 (32.61)    | 165 (31.31)   | 0.74283 |
| Primary infertility      | 86 (67.19)    | 362 (68.69)   |         |
| Treatment                |               |               |         |
| ICSI                     | 21 (16.41)    | 84 (15.94)    | 0.89723 |
| IVF                      | 107 (83.59)   | 443 (84.06)   |         |
| Proposal type            |               |               |         |
| Follicular phase long-acting protocol* | 62 (48.44) | 388 (73.62) | <0.0001 |
| Long-acting protocol†    | 66 (51.56)    | 139 (26.38)   |         |

*p < 0.05.
Data are mean ± standard deviation or N (% of response group). FSH, follicle-stimulating hormone; E2, estradiol; P4, progesterone; LH, luteinizing hormone; PRL, pituitary prolactin; T, testosterone; BMI, body mass index.

Ovarian Induction Characteristics

Compared with the normal group, the OHSS group was associated with fewer starting dosages of Gn, a longer length of stimulation, more retrieved oocytes, a lower MII oocyte rate, and fewer good-quality embryos, as shown in Table 3. We further analyzed the above indicators by comparing them between the mild and moderate OHSS groups (Table 4). The mild OHSS patients were associated with more starting dosages of Gn (117.77 ± 25.90 vs 110.39 ± 21.12, P=0.0003), a shorter length of stimulation (13.66 ± 3.14 vs 14.22 ± 2.94, P=0.0258), fewer retrieved oocytes (19.40 ± 6.29 vs 23.65 ± 7.94, P<0.0001), a lower MII oocyte rate (46.61 ± 43.10 vs 64.60 ± 36.94, P=0.0002), and a higher rate of good-quality embryos (53.91 ± 22.77 vs 47.90 ± 21.74, P=0.0057).

Hormone Level and Ovary Size During Controlled Ovarian Stimulation

The mild OHSS group had a smaller ovarian volume before and after HCG trigger (P<0.0001, left ovary size on HCG was 5.38 ± 0.85 vs 5.86 ± 0.95, P<0.0001, right ovary size on HCG was 5.89 ± 0.95 vs 6.38 ± 0.91; P<0.0001, left ovary size on HCG+3 7.00 ± 0.68 vs 8.55 ± 1.13, P<0.0001, right ovary size on HCG+3 7.04 ± 0.62 vs 8.80 ± 1.08). The moderate OHSS group had a much higher serum E2 level (P=0.0008, 2026.29 ± 730.84 vs 1790.31 ± 693.25) and thicker endometrium on HCG+3 (P=0.0386, 11.88 ± 2.21 vs 11.43 ± 2.15), as shown in Table 5. Meanwhile, there was a significant difference in the number of women with uterine effusion and cystocele on HCG (P=0.00129, 23 vs 171) between the mild OHSS and moderate OHSS groups.

Factors Associated With OHSS and OHSS Severity in Women With PCOS

Logistic regression analysis, incorporating conventional markers such as age, BMI, baseline hormone levels and AFC in the model, showed that only baseline hormone levels (FSH, E2, PRL, and LH) and AFC were significantly predictive of OHSS (Table 6). Among the patients with values less than the median values of the reference groups, the median values for FSH, E2, PRL, and LH were 5.74, 38.65, 14.95, and 7.02, respectively. Among the variables analyzed, AFC was the best predictor of OHSS (OR [95% CI]: 7.04 ± 0.62 vs 8.80 ± 1.08).
who had a potential risk of OHSS severity was only of a modest degree (FSH (OR [95% CI]: 0.71(0.47–1.08)), E2 (OR [95% CI]: 1.61(1.04–2.47)), T (OR [95% CI]: 1.15(0.74–1.79)). Among the patients with values less than the median values of the reference groups, the median values for FSH, E2 and T were 5.49, 37.94, and 0.37, respectively. In addition, AFC was another predictive factor of OHSS severity (OR [95% CI]: 1.30 (0.80–2.10)), and the median AFC was 24. Among all the variables analyzed, the basal serum E2 level was the best predictor of OHSS severity.

**DISCUSSION**

Our study retrospectively analyzed 2,699 infertile women with PCOS who underwent their first ovarian stimulation cycles. During ovarian stimulation, PCOS patients with OHSS were younger and had lower BMIs, higher AFCs, and lower levels of basal serum FSH and E2. Moreover, PCOS patients with OHSS had more retrieved oocytes, a lower rate of MII oocytes and a lower rate of good-quality embryos. Only the AFC and basal serum levels of FSH and E2 were significantly correlated with OHSS. These results suggested that the AFC is the most important risk factor for OHSS in women with PCOS.

To further investigate the risk factors affecting OHSS severity, mild and moderate OHSS patients were compared. Compared with the moderate OHSS group, the mild OHSS group was older and had higher basal serum FSH and lower serum E2 and T levels. However, BMI and AFC were not different between the groups. Otherwise, the mild OHSS group had more starting doses of Gn, a shorter length of stimulation, fewer retrieved oocytes, a lower MII oocyte rate, and a greater number of good-quality embryos. As risk factors for OHSS, FSH, E2, and AFC were also significantly correlated with OHSS severity. The basal serum E2 level demonstrated the best correlation among them.

**TABLE 6 | Logistic regression analysis for OHSS.**

| Age        | Beta  | Standard Error | Wald Chi-Square Value | P value | OR (95% CI) |
|------------|-------|----------------|-----------------------|---------|-------------|
| ≤25 y      | 0.1877 | 0.0797         | 5.5501                | 0.0185  | 1.14(0.85–1.53) |
| 25–30 y    | 0.0067  | 0.0928         | 0.0052                | 0.9427  | 0.95(0.69–1.31) |
| >35 y      | -0.2508 | 0.1537         | 2.664                 | 0.1026  | 0.74(0.46–1.17) |
| BMI        | 18.5–23.9  | -0.0437       | 0.0734                | 0.354   | 0.5519      |
| >27.9      | -0.0782  | 0.0926         | 0.713                 | 0.3985  | 0.82(0.62–1.09) |
| Antral follicular count* | 0.6275 | 0.1098 | 32.64 | <.0001 | 1.87(1.51–2.32) |
| Baseline hormone levels |  |  |  |  |  |
| FSH (mIU/ml)* | -0.3937 | 0.0994 | 15.7017 | <.0001 | 1.08(1.05–1.11) |
| E2 (pg/ml)*  | -0.1447 | 0.0979 | 2.1865 | 0.1392 | 1.05(0.88–1.25) |
| PRL (ng/ml)* | 0.2823 | 0.0972 | 8.4305 | 0.0007 | 1.33(1.10–1.60) |
| LH (mIU/ml)* | 0.313  | 0.1024 | 9.3384 | 0.0022 | 1.37(1.12–1.67) |
| ICSI       | -0.1103 | 0.0634 | 3.0246 | 0.082  | 0.80(0.63–1.03) |
| Long-acting protocol | -0.8048 | 0.1003 | 64.4436 | <.0001 | 0.45(0.37–0.54) |

*Select patients with less than the median value served as the reference group. The median value for the antral follicular count, FSH, E2, PRL, and LH was 24, 5.74, 38.65, 14.95, and 7.02, respectively.

FSH, follicle-stimulating hormone; E2, estradiol; P4, progesterone; LH, luteinizing hormone; PRL, pituitary prolactin; BMI, body mass index; ICSI, intracytoplasmic sperm injection.
Female Age and OHSS

Female age is a major factor influencing fertility. Increases in age reduce the reproductive capacity of women due to a reduced ovarian reserve, poor oocyte quality, and an increased prevalence of embryonic aneuploidy (21–23). Moreover, this study shows that age may also be used to assess the risk of OHSS and OHSS severity. Young women with high AFCs, high serum E2 levels and a high number of retrieved oocytes are more susceptible to OHSS. Two prospective studies and five retrospective studies that evaluated the effect of age on OHSS development showed that younger age was indeed a risk factor (24–28). Patient age has predictive significance for the occurrence of moderate-to-severe OHSS. The younger the patients are, the greater the possibility of developing severe OHSS. In our study of patients with PCOS, the OHSS group was younger, but age was not a risk factor for OHSS. The incidence rate of OHSS for patients aged between 25 and 30 years old, was compared with those aged ≤ 25 years old, was increased (OR [95% CI]: 1.14 [0.85–1.53]), but the severity of OHSS for the same age stratification was decreased (OR [95% CI]: 0.79 [0.39–1.60]). This finding was probably because the patients in our study were generally young, which was inconsistent with previous studies.

BMI and OHSS

BMI is another patient characteristic that was considered when assessing the risk of developing OHSS and OHSS severity. The initial Gn dosage for COH was determined based on patient characteristics, including BMI. A prospective observational cohort study showed that women with a BMI of ≥25 kg/m² had significantly fewer mature oocytes, required a higher total dose of rFSH and had a higher risk of developing severe OHSS (29). However, a cohort study of 262 IVF cycles showed that BMI had no predictive value for OHSS (30). In contrast, our results showed that whereas there was no significant difference in BMI between OHSS patients with PCOS and patients with PCOS but no OHSS, OHSS patients had a lower BMI (23.72 ± 3.54 vs 24.08 ± 3.57). However, patients with mild OHSS and patients with moderate OHSS showed little difference in terms of BMI. Therefore, the influence of BMI on the development of OHSS and OHSS severity require further study.

AFC and OHSS

Markers for ovarian reserve, especially serum AMH and AFC, may also be used to assess the risk of OHSS. The basal serum AMH level correlates well with the antral follicle count ultrasonographic findings (31). Regression analysis resulting from a retrospective study revealed that the AFC (OR, 95% CI; 4.3, 2.7–6.9) was the most important predictor of OHSS among non-polycystic ovary (NPCO) patients undergoing IVF/ICSI (24). In addition, Pelinalso et al. showed that AFC (AUC = 0.74) had moderate accuracy for predicting OHSS (32). Our study highlights that the mean FSH level was significantly lower (P < 0.0001) in women with OHSS than in those without OHSS. In a prospective analysis of 1,012 first ART cycles, the risk of OHSS increased from 2.2% in women with AFC < 24 to 8.6% in those with AFC≥24. Similarly, data from our study showed that the AFC cutoff value for OHSS in patients with PCOS was 24. In addition, AFC ≥24 correlated with an increased risk of moderate-to-severe OHSS. Compared with patients with mild OHSS, patients with moderate OHSS had a higher cutoff value (22.80 ± 2.84 vs 23.13 ± 2.42). Based on the data, our study shows that AFC predicts OHSS. Thus, knowledge of AFC levels is crucial in planning and managing the risks of over response and OHSS.

Basal Serum E2, the Number of Oocytes Retrieved and OHSS

The development of OHSS is almost always accompanied by elevated estradiol (E2) levels, and estrogen has been implicated as a potential etiologic factor, one of the possible reason is that when the estradiol elevated, capillary permeability and the chemical mediators or precursors that augment fluid extravasation increased and thus moderate OHSS developed (33). The results from our study indicate that the level of basal serum E2 is predictive of OHSS, and the differences between the mild OHSS group and the moderate OHSS group have statistical significance (38.05 ± 30.90 vs 45.40 ± 29.61 P<0.001). Therefore, basal serum E2 showed a stronger correlation with OHSS severity and needs further study. A previous study showed that the number of retrieved oocytes is a risk factor for the occurrence of OHSS, and those with very high blood E2 levels and too many oocytes retrieved have an increased incidence of moderate-to-severe OHSS (34). In our study, the number of retrieved oocytes in the OHSS group was higher than...
that in the normal group (22.96 ± 7.93 vs 15.31 ± 6.84), but the rate of good-quality embryos was lower (49.06 ± 22.13 vs 58.54 ± 27.86).

In addition, compared with the mild OHSS group, the moderate OHSS group generally had more oocytes retrieved. These results may help clinicians pay more attention to the basal serum E2 and the number of retrieved oocytes of patients with PCOS, which may prevent the occurrence of OHSS.

**Strengths and Limitations**

Our study revealed that AFCs have the most important impact on the occurrence of OHSS, especially in patients with PCOS. However, our study was conducted retrospectively and only involved a single medical center. In addition, serum AMH was measured in only a few patients, and thus these measurements were not included in this study. Finally, all patients undergoing ovarian induction were treated with a gonadotropin releasing hormone (GnRH) agonist protocol, weakening the generalizability of the findings.

In summary, AFC is an independent risk factor for OHSS in women with PCOS undergoing their first ovarian stimulation cycle. Besides, basal serum E2 is a predictive factor for OHSS severity. Meanwhile, patients with PCOS undergoing IVF/ICSI who are at risk of OHSS can be identified by careful ultrasonography of the ovaries before treatment. AFC >24 specifically is associated with an increased risk of OHSS, and the cutoff value is the same with NPCO patients, which indicates that patients with PCOS do not need the use of GnRH agonist cycles with low-dose FSH. This strategy will guide cycles of fresh embryo transfer instead of using a freeze-all strategy, improve the rates of live birth and lower the risks of OHSS.

**Database**

The data were obtained from the ART electronic medical record system (CCRM) at the Reproductive Medicine Center of the First Affiliated Hospital of Zhengzhou University (a tertiary-care teaching hospital, Zhengzhou, China). All medical histories, ART treatment processes and the outcomes of every cycle are recorded in the CCRM. The records are validated by the Technical Standard for Human Assisted Reproduction issued by the Chinese Ministry of Health. The surveillance staff consults the patient information and performs quality control periodically.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

**REFERENCES**

1. Luke B, Brown MB, Morbeck DE, Hudson SB, Coddington CC3rd, Stern JE. Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome. *Fertil Steril* (2010) 94:1399–404. doi: 10.1016/j.fertnstert.2009.05.092

2. Steward RG, Lan L, Shah AA, Yeh JS, Price TM, Goldfarb JM, et al. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. *Fertil Steril* (2014) 101:967–73. doi: 10.1016/j.fertnstert.2013.12.026

3. Jayaprakasan K, Chan Y, Islam R, Haoula Z, Hopkisson J, Coomarasamy A, et al. Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. *Fertil Steril* (2012) 98:657–63. doi: 10.1016/j.fertnstert.2012.05.042

4. Nelson SM. Prevention and management of ovarian hyperstimulation syndrome. *Thromb Res* (2017) 151(Suppl 1):S61–4. doi: 10.1016/S0049-3848(17)30070-1

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Research Ethics Committee of the First Affiliated Hospital of Zhengzhou University.

**AUTHOR CONTRIBUTIONS**

BS and YM: designed study, analyzed data, and drafted the manuscript. LL: revised the manuscript. LH, FW, and SD: collected data. LH and YZ: reviewed the manuscript. YS: study conceptualization and review. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was funded by the International (Regional) Cooperation and Exchange (ICE) Projects of the National Natural Science Foundation of China (NSFC) (FDN-81820108016), the Chinese Medical Association Clinical Medical Research Special Fund Project (FDN-17020190688), the Medical Science and Technology Research Project Joint Co-construction Project of Henan Province (FDN-2018020116), and the Henan Provincial Higher Education Key Research Project Plan (FDN-19A320056).

**ACKNOWLEDGMENT**

The authors thank the staff of Reproductive Medicine Center, First Affiliated Hospital of Zhengzhou University for their cooperation and support.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2020.615957/full#supplementary-material
5. Kurioka H, Takahashi K, Kita N, Noda Y. Hemorrhagic ovarian cyst without peritoneal bleeding in a patient with ovarian hyperstimulation syndrome: case report. Clin Med (Lond) (2005) 118:1571–81.

6. Corbetti S, Shmorgun D, Claman P. The prevention of ovarian hyperstimulation syndrome. J Obstet Gynaecol Can (2014) 36(11):1024–33. doi: 10.1016/S1710-2163(15)30417-5

7. Lee TS, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, et al. Serum AMH and estradiol levels as predictors of OHSS in ART cycles. Hum Reprod (2008) 23 (1):160–7. doi: 10.1093/humrep/dem254

8. Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update (2008) 14(4):321–33. doi: 10.1093/humupd/dmn008

9. Liu M, Xie S, Zhou J. Use of animal models for the imaging and quantification of angiogenesis. Exp Anim (2018) 67(1):1–6. doi: 10.1538/expanim.17-0054

10. Brassard M, Aïn-Melk Y, Baillargeon JP. Basic infertility including polycystic ovarian syndrome. Pract Gynecol Obstet (2008) 2:147–52. doi: 10.17219/acem/92916

11. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet (1997) 68(6):1017–21. doi: 10.1016/S0140-6736(07)61345-2

12. Groth SW. Adiponectin and polycystic ovary syndrome. Biol Res Nurs (2010) 12(1):62–72. doi: 10.1177/1099800410371824

13. Mathur RS, Tan BK. British fertility society policy and practice committee: definition, incidence, and classification. Semin Reprod Med (2010) 28(4):827–33. doi: 10.1016/j.srmed.2010.02.013

14. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril (2000) 73:901–7. doi: 10.1016/S0015-0282(00)00492-1

15. Aboulghar MA, Mansour RT, Serour GI, Ramzy AM, Amin YM, Mansour RT, et al. Oocyte quality in patients with severe ovarian hyperstimulation syndrome. Fertil Steril (1997) 68(6):1017–21. doi: 10.1016/S0015-0282(97)00409-3

16. Fábregues F, Peñarrubia J, Vidal E, Casals G, Vanrell JA. Basal LH, FSH, insulin and cortisol levels as predictors of OHSS in ART cycles. Hum Reprod (2000) 15(4):257–68. doi: 10.1093/humrep-deq028

17. Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a self-controlled clinical study. Fertil Steril (2004) 82(4):827–33. doi: 10.1016/j.fertnstert.2004.02.131

18. Sahu B, Ozturk O, Ranierrì M, Serhal P. Comparison of oocyte quality and intracytoplasmic sperm injection outcome in women with isolated polycystic ovaries or polycystic ovarian syndrome. Arch Gynecol Obstet (2008) 277 (3):239–44. doi: 10.1007/s00404-007-0462-x

19. Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril (2016) 106(7):1634–47. doi: 10.1016/j.fertnstert.2016.08.048

20. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCs Society (AES). AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME-PART 1. Endocr Pract (2015) 21(11):1291–300. doi: 10.4188/EP15748.DSC

21. Zivi E, Simion A, Laufer N. Ovarian hyperstimulation syndrome: definition, incidence, and classification. Vitam Horm (2010) 80:441–7. doi: 10.1016/S0083-0330(09)03699-0

22. Blumenfeld Z. The Ovarian Hyperstimulation Syndrome. Vitam Horm (2018) 107:423–51. doi: 10.1016/bs.vh.2018.01.018

23. Esteeves SC, Carvalho JF, Martinsinho CD, Melo AA, Bento FC, Humaidan P, et al. Estimation of age-dependent decrease in blastocyst euploidy by next generation sequencing: development of a novel prediction model. Panninewa Med (2019) 61(1):3–10. doi: 10.23736/s0031-0808.18.03507-3

24. Blumenfeld Z. Ovarian hyperstimulation syndrome: a clinical report on 4,894 consecutive ART treatment cycles. Reprod Biol Endocrinol (2015) 13:66. doi: 10.1186/s12958-015-0067-3

25. Johnson MD, Williams SL, Seager CK, Liu JH, Barker NM, Hurd WW. Relationship between human chorionic gonadotropin serum levels and the risk of ovarian hyperstimulation syndrome. Gynecol Endocrinol (2014) 30:294–7. doi: 10.3109/09513590.2013.875998

26. Sousa M, Cunha M, Teixeira da Silva J, Oliveira C, Silva J, Viana P, et al. Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles. Reprod Biol Endocrinol (2015) 13:66. doi: 10.1186/s12958-015-0067-3

27. Johnson MD, Williams SL, Seager CK, Liu JH, Barker NM, Hurd WW. Relationship between human chorionic gonadotropin serum levels and the risk of ovarian hyperstimulation syndrome. Gynecol Endocrinol (2014) 30:294–7. doi: 10.3109/09513590.2013.875998

28. Sousa M, Cunha M, Teixeira da Silva J, Oliveira C, Silva J, Viana P, et al. Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles. Reprod Biol Endocrinol (2015) 13:66. doi: 10.1186/s12958-015-0067-3

29. Johnson MD, Williams SL, Seager CK, Liu JH, Barker NM, Hurd WW. Relationship between human chorionic gonadotropin serum levels and the risk of ovarian hyperstimulation syndrome. Gynecol Endocrinol (2014) 30:294–7. doi: 10.3109/09513590.2013.875998

30. Sousa M, Cunha M, Teixeira da Silva J, Oliveira C, Silva J, Viana P, et al. Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles. Reprod Biol Endocrinol (2015) 13:66. doi: 10.1186/s12958-015-0067-3

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Copyright © 2021 Sun, Ma, Li, Hu, Wang, Zhang, Dai and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.